Alpha-1 Foundation
15
3
5
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.7%
1 terminated/withdrawn out of 15 trials
88.9%
+2.4% vs industry average
7%
1 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Alpha-1 Antitrypsin Deficiency Adult Liver Study
Role: collaborator
PiMZ Longitudinal Cohort (PiMZ Logic)
Role: collaborator
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
Role: collaborator
Alpha-1 Foundation DNA and Tissue Bank
Role: collaborator
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Role: collaborator
COPD Exacerbation Blood and Urine Biomarkers Study
Role: collaborator
Alpha-1 Research Registry
Role: lead
Alpha-1 Foundation Research Registry
Role: collaborator
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Role: collaborator
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
Role: collaborator
The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency
Role: collaborator
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency
Role: collaborator
4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
Role: collaborator
Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients
Role: collaborator
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
Role: lead
All 15 trials loaded